Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

Authors

Keywords

Journal

Volume 33, Issue 8, Pages 828-833

Publisher

Ovid Technologies (Wolters Kluwer Health)

Online

2010-09-14

DOI

10.1097/cji.0b013e3181eec14c

References

View 1 related references

Discuss science. Find collaborators. Network.

Join a conversation

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started